INDV INDIVIOR PLC

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th  

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th  

RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.

Access to the Live Webcast Presentation:

The webcast event and materials can be accessed on the “Investors” section of the company’s website at before the event begins.

Live webcast link:

Participants may access the presentation telephonically by registering with the following link:

(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)

A replay of the presentation will be available at .

About Indivior

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities – we are powering recovery and renewing hope. Visit  to learn more. Connect with Indivior on LinkedIn by visiting . 

For Further Information

Investors:

Jason Thompson

Indivior Pharmaceuticals

Tel: 804-402-7123

E-mail:

Media:

Cassie France-Kelly

Indivior Pharmaceuticals

Tel: 804-594-0836

E-Mail:



EN
09/04/2026

Underlying

INDVINDIVIOR PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INDIVIOR PLC

 PRESS RELEASE
Free
INDV INDIVIOR PLC

Indivior to Report First Quarter 2026 Financial Results and Host Webca...

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th   RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT. Access to the Live Webcast Presentation: The webcast event and materials can be...

April 9, 2026 1 EN
 PRESS RELEASE
Free
INDV INDIVIOR PLC

New Cost Impact Model Highlights Potential for Monthly Injectable Bupr...

New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities Model estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from a new cost impact model published in The Journal of Current Medical Research and Opinion, estimating that the use of extended-release buprenorphine, a monthly injectable commercially a...

March 31, 2026 1 EN
 PRESS RELEASE
Free
INDV INDIVIOR PLC

National Survey Finds Only 58% of U.S. Correctional Facilities Offer M...

National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder Jails outpace prisons in offering MOUD, but regional disparities and limited treatment access persist across the U.S.Qualitative feedback points to need for greater reentry support, housing, care coordination, and provider training RICHMOND, Va., March 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals Inc. (Nasdaq: INDV) announced results from a cross-sectional survey published in the Journal of Correctional Health Care that reveal critical gaps in the availability of medications ...

March 17, 2026 1 EN
 PRESS RELEASE
Free
INDV INDIVIOR PLC

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offeri...

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $400,000,000 aggregate princ...

March 13, 2026 1 EN
 PRESS RELEASE
Free
INDV INDIVIOR PLC

Indivior Announces Proposed Convertible Senior Notes Offering

Indivior Announces Proposed Convertible Senior Notes Offering RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Indivior also expects to grant the initial purchasers of the notes a 30-day option to...

March 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch